{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:25:42Z","timestamp":1788297942148,"version":"build-2803163510"},"reference-count":106,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","award":["2027497"],"award-info":[{"award-number":["2027497"]}],"id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DE240101056"],"award-info":[{"award-number":["DE240101056"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,7]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There is substantial literature on opioid pharmacotherapies from a service user perspective, mostly focused on methadone and buprenorphine. However, as a relatively new formulation, much less is known about user experiences and views of Long-Acting Injectable Buprenorphine (LAIB). To date, no published reviews have qualitatively described LAIB service user experience. The objective of this scoping review is to identify and describe the peer-reviewed qualitative studies examining the service user experience of LAIB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This scoping review will follow the methodology described by Arksey and O\u2019Malley, further adapted by Levac\n                      <jats:italic>et al<\/jats:italic>\n                      and others. The search strategy will be developed in collaboration with an expert librarian and will include searches of Medline, Embase, PsycINFO, CINAHL, Scopus and Web of Science as well as citation chaining. The search dates will range from 2016, when LAIB was first approved, to the date of the final search. Included studies will investigate the perspectives and experiences of LAIB treatment participants with opioid dependence, within an Opioid Treatment Programme (OTP). For service users, the pharmacological formulation of LAIB significantly reshapes both the clinical practice and the social dynamics within OTPs. To effectively capture the depth and nuance of service users\u2019 experiences, this review will be limited to qualitative, mixed-method, case series or case study designs, with a further restriction to peer-reviewed articles published in English. Identified references, with duplicates removed, will be imported into Covidence for title\/abstract screening, full-text review and data extraction by two independent reviewers. All decisions on data inclusion or exclusion will be by consensus agreement, using a third reviewer if necessary. A living experience researcher will lead analysis of manuscript content in NVivo using inductive coding to produce a descriptive thematic analysis. The narrative summary will present key study characteristics, quality appraisal and synthesised findings that describe service user experiences and perspectives of LAIB, guided by the Systematic Reviews and Meta-Analysis for Scoping Reviews checklist.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This scoping review undertakes secondary analysis of data in the public domains only and thus does not require ethics approval given no participants are directly involved. The results of the review will be published in a peer-reviewed journal, presented at relevant academic and community conferences, and discussed and disseminated to\/with community organisations, service users and policy-makers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data statement<\/jats:title>\n                    <jats:p>\n                      Prepublication history and additional supplemental material for this paper are available online. To view these files, visit: Open Science Framework\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.17605\/OSF.IO\/XMHKN\">https:\/\/doi.org\/10.17605\/OSF.IO\/XMHKN<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106054","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:20:29Z","timestamp":1765974029000},"page":"e106054","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Qualitative evidence of service user experiences and perspectives on long-acting injectable buprenorphine for opioid treatment: protocol for a scoping review"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7264-2676","authenticated-orcid":false,"given":"Charles","family":"Henderson","sequence":"first","affiliation":[{"name":"Epidemiology and Preventative Medicine, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Walker","sequence":"additional","affiliation":[{"name":"Epidemiology and Preventative Medicine, Burnet Institute, Melbourne, Victoria, Australia"},{"name":"School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia"},{"name":"Curtin University, Perth, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachery","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"National Drug and Alcohol Research Centre, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-5463","authenticated-orcid":false,"given":"Lorena","family":"Romero","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"The Alfred, Alfred Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Stoov\u00e9","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"},{"name":"Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2026010703472598000_15.12.e106054.1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/inm.12523","article-title":"Readiness and recovery: Transferring between methadone and buprenorphine\/naloxone for the treatment of opioid use disorder","volume":"28","author":"Bishop","year":"2019","journal-title":"Int J Ment Health Nurs"},{"key":"2026010703472598000_15.12.e106054.2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"2026010703472598000_15.12.e106054.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"2026010703472598000_15.12.e106054.4","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamapsychiatry.2018.1214","article-title":"Risk of Heroin Dependence in Newly Incident Heroin Users","volume":"75","author":"Santiago Rivera","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"2026010703472598000_15.12.e106054.5","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/M18-1652","article-title":"The Next Stage of Buprenorphine Care for Opioid Use Disorder","volume":"169","author":"Martin","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026010703472598000_15.12.e106054.6","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000052"},{"key":"2026010703472598000_15.12.e106054.7","doi-asserted-by":"crossref","first-page":"108776","DOI":"10.1016\/j.jsat.2022.108776","article-title":"Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health","volume":"139","author":"Martin","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2026010703472598000_15.12.e106054.8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026010703472598000_15.12.e106054.9","unstructured":"Lancaster K , Seear K , Ritter A . DPMP monograph series. In: Monograph No. 26: reducing stigma and discrimination for people experiencing problematic alcohol and other drug use. National Drug and Alcohol Research Centre (NDARC), University of NSW, 2018. Available: http:\/\/doi.org\/10.26190\/5b8746fe72507"},{"key":"2026010703472598000_15.12.e106054.10","unstructured":"Gowing L , Ali R , Dunlop A , et al . National guidelines for medication-assisted treatment of opioid dependence, report no.: 10253. Commonwealth of Australia, 2014."},{"key":"2026010703472598000_15.12.e106054.11","doi-asserted-by":"publisher","DOI":"10.1080\/10826080802483936"},{"key":"2026010703472598000_15.12.e106054.12","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1991.10472226"},{"key":"2026010703472598000_15.12.e106054.13","doi-asserted-by":"crossref","unstructured":"Ling W , Shoptaw S . Opioid use disorder pharmacotherapy: a historical perspective on how we practice, and why. In: Wakeman SE , Rich JD , eds. Treating opioid use disorder in general medical settings. Switzerland: Springer, 2021: 9\u201321.","DOI":"10.1007\/978-3-030-80818-1_2"},{"key":"2026010703472598000_15.12.e106054.14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.194.6.646"},{"key":"2026010703472598000_15.12.e106054.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06352.x"},{"key":"2026010703472598000_15.12.e106054.16","doi-asserted-by":"crossref","first-page":"108781","DOI":"10.1016\/j.jsat.2022.108781","article-title":"Long-acting depot buprenorphine in people who are homeless: Views and experiences","volume":"139","author":"Matheson","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2026010703472598000_15.12.e106054.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2005.02.007"},{"key":"2026010703472598000_15.12.e106054.18","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"1","author":"Mattick","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010703472598000_15.12.e106054.19","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010703472598000_15.12.e106054.20","unstructured":"NSW Ministry of Health . NSW clinical guidelines: treatment of opioid dependence NSW, Report No.: 978-1-76000-818-5. NSW, 2018."},{"key":"2026010703472598000_15.12.e106054.21","doi-asserted-by":"crossref","first-page":"104255","DOI":"10.1016\/j.drugpo.2023.104255","article-title":"Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022","volume":"123","author":"Bharat","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-019-1237-8","article-title":"Quality of life and well-being from the perspective of patients on opioid agonist maintenance treatment: study protocol for a systematic review of qualitative research and a scoping review of measures","volume":"8","author":"Sol\u00e0","year":"2019","journal-title":"Syst Rev"},{"key":"2026010703472598000_15.12.e106054.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m710","article-title":"Management of dependent use of illicit opioids","volume":"368","author":"Mitchell","year":"2020","journal-title":"BMJ"},{"key":"2026010703472598000_15.12.e106054.24","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-022-00510-1","article-title":"Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program","volume":"18","author":"Reed","year":"2023","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2026010703472598000_15.12.e106054.25","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"2026010703472598000_15.12.e106054.26","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S72543"},{"key":"2026010703472598000_15.12.e106054.27","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA) . Medications for opioid use disorder. SAMHSA, 2021."},{"key":"2026010703472598000_15.12.e106054.28","first-page":"362","article-title":"Clinical Pearls for Buprenorphine Treatment","volume":"11","author":"Walton","year":"2021","journal-title":"Prim Health Care"},{"key":"2026010703472598000_15.12.e106054.29","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1097\/ADM.0000000000001048","article-title":"Patient Satisfaction With Standard Methadone and Flexible Buprenorphine\/Naloxone Models of Care: Results From a Pragmatic Randomized Controlled Clinical Trial","volume":"17","author":"Hassan","year":"2023","journal-title":"J Addict Med"},{"key":"2026010703472598000_15.12.e106054.30","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S109919"},{"key":"2026010703472598000_15.12.e106054.31","article-title":"Opioid agonist treatment for people who are dependent on pharmaceutical opioids","volume":"9","author":"Nielsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010703472598000_15.12.e106054.32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"2026010703472598000_15.12.e106054.33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2020.01.009","article-title":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders","volume":"111","author":"Saunders","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"2026010703472598000_15.12.e106054.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145817","article-title":"Patient Preferences and Shared Decision Making in the Treatment of Substance Use Disorders: A Systematic Review of the Literature","volume":"11","author":"Friedrichs","year":"2016","journal-title":"PLoS ONE"},{"key":"2026010703472598000_15.12.e106054.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.01.019"},{"key":"2026010703472598000_15.12.e106054.36","doi-asserted-by":"crossref","first-page":"209138","DOI":"10.1016\/j.josat.2023.209138","article-title":"Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis","volume":"154","author":"Muthulingam","year":"2023","journal-title":"J Subst Use Addict Treat"},{"key":"2026010703472598000_15.12.e106054.37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1455072518814313","article-title":"Polluting pharmaceutical atmospheres: Compulsion, resistance, and symbolism of buprenorphine in Norway","volume":"36","author":"Bartoszko","year":"2019","journal-title":"Nordic Studies on Alcohol and Drugs"},{"key":"2026010703472598000_15.12.e106054.38","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/01612840.2015.1074769","article-title":"From Resistance to Existence-Experiences of Medication-Assisted Treatment as Disclosed by People with Opioid Dependence","volume":"36","author":"Lindgren","year":"2015","journal-title":"Issues Ment Health Nurs"},{"key":"2026010703472598000_15.12.e106054.39","unstructured":"Guarinieri M . Extended-release opioid agonist products. a community position statement. International Network of People who Inject Drugs [INPUD]; 2019. Available: https:\/\/inpud.net\/position-papers"},{"key":"2026010703472598000_15.12.e106054.40","doi-asserted-by":"crossref","first-page":"103041","DOI":"10.1016\/j.drugpo.2020.103041","article-title":"Biotechnologies and the future of opioid addiction treatments","volume":"88","author":"Wolfe","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1526-4637.2011.01117.x","article-title":"Police officer, deal-maker, or health care provider? Moving to a patient-centered framework for chronic opioid management","volume":"12","author":"Nicolaidis","year":"2011","journal-title":"Pain Med"},{"key":"2026010703472598000_15.12.e106054.42","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1409722"},{"key":"2026010703472598000_15.12.e106054.43","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12175575","article-title":"Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder","volume":"12","author":"Maremmani","year":"2023","journal-title":"J Clin Med"},{"key":"2026010703472598000_15.12.e106054.44","first-page":"5","article-title":"How should methadone and buprenorphine treatment be organized and regulated? A comparison between two systems in the context of a EUROPAD Conference in Brussels","volume":"14","author":"Ulmer","year":"2012","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"2026010703472598000_15.12.e106054.45","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-023-00551-0","article-title":"Patients\u2019 goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study","volume":"18","author":"Neale","year":"2023","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2026010703472598000_15.12.e106054.46","first-page":"1","article-title":"Use of Pharmacotherapies in the Treatment of Alcohol Use Disorders and Opioid Dependence in Primary Care","volume":"2015","author":"Lee","year":"2015","journal-title":"Biomed Res Int"},{"key":"2026010703472598000_15.12.e106054.47","doi-asserted-by":"crossref","first-page":"104399","DOI":"10.1016\/j.drugpo.2024.104399","article-title":"The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients\u2019 experiences","volume":"127","author":"Barnett","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.48","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/00914509221140959","article-title":"The Social, Material, and Temporal Effects of Monthly Extended-Release Buprenorphine Depot Treatment for Opioid Dependence: An Australian Qualitative Study","volume":"50","author":"Lancaster","year":"2023","journal-title":"Contemp Drug Probl"},{"key":"2026010703472598000_15.12.e106054.49","doi-asserted-by":"crossref","first-page":"104359","DOI":"10.1016\/j.drugpo.2024.104359","article-title":"Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence","volume":"126","author":"Lancaster","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.50","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51098"},{"key":"2026010703472598000_15.12.e106054.51","unstructured":"European Medicines Agency . Buvidal EPAR product information. Amsterdam, 2018. Available: www.ema.europa.eu"},{"key":"2026010703472598000_15.12.e106054.52","unstructured":"Indivior . Sublocade prescribing information. 2023. Available: https:\/\/www.indivior.com\/en\/products"},{"key":"2026010703472598000_15.12.e106054.53","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026010703472598000_15.12.e106054.54","unstructured":"Lintzeris N , Dunlop A , Schulz M . Long-acting injectable buprenorphine (LAIB) for opioid dependence treatment: practice guide (2nd Ed). Sydney (AU): NSW Ministry of Health, 2024."},{"key":"2026010703472598000_15.12.e106054.55","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S155843"},{"key":"2026010703472598000_15.12.e106054.56","doi-asserted-by":"crossref","first-page":"104470","DOI":"10.1016\/j.drugpo.2024.104470","article-title":"\u201cMatters-of-concern\u201d associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study","volume":"129","author":"Parkin","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.57","doi-asserted-by":"crossref","first-page":"104221","DOI":"10.1016\/j.drugpo.2023.104221","article-title":"Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study","volume":"122","author":"Parkin","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.58","doi-asserted-by":"crossref","first-page":"104390","DOI":"10.1016\/j.drugpo.2024.104390","article-title":"96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial","volume":"127","author":"Farrell","year":"2024","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.59","doi-asserted-by":"crossref","first-page":"111032","DOI":"10.1016\/j.drugalcdep.2023.111032","article-title":"Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada","volume":"254","author":"Iacono","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"2026010703472598000_15.12.e106054.60","doi-asserted-by":"crossref","first-page":"103492","DOI":"10.1016\/j.drugpo.2021.103492","article-title":"Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence","volume":"100","author":"Farrell","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.61","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/add.14941","article-title":"Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia","volume":"115","author":"Larance","year":"2020","journal-title":"Addiction"},{"key":"2026010703472598000_15.12.e106054.62","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.drugalcdep.2021.108959","article-title":"Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients\u2019 experiences in Australia","volume":"227","author":"Barnett","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2026010703472598000_15.12.e106054.63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/SAR.S266838","article-title":"Patient-Reported Outcomes, Experiences and Satisfaction with Weekly and Monthly Injectable Prolonged-Release Buprenorphine","volume":"11","author":"Parsons","year":"2020","journal-title":"Subst Abuse Rehabil"},{"key":"2026010703472598000_15.12.e106054.64","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-022-00474-2","article-title":"Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study","volume":"17","author":"Johnson","year":"2022","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2026010703472598000_15.12.e106054.65","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/dar.13616","article-title":"Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study","volume":"42","author":"Allen","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"2026010703472598000_15.12.e106054.66","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/add.16171","article-title":"How do patients feel during the first 72\u2009h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis","volume":"118","author":"Neale","year":"2023","journal-title":"Addiction"},{"key":"2026010703472598000_15.12.e106054.67","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/09687637.2023.2165041","article-title":"Qualitative study of patients\u2019 decisions to initiate injectable depot buprenorphine for opioid use disorder: the role of information and other factors","volume":"31","author":"Neale","year":"2024","journal-title":"Drugs Educ Prev Policy"},{"key":"2026010703472598000_15.12.e106054.68","doi-asserted-by":"crossref","first-page":"104002","DOI":"10.1016\/j.drugpo.2023.104002","article-title":"\u201cI just thought that was the best thing for me to do at this point\u201d: Exploring patient experiences with depot buprenorphine and their motivations to discontinue","volume":"115","author":"Clay","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.69","article-title":"A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder","volume":"2","author":"Cernasev","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"key":"2026010703472598000_15.12.e106054.70","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like 'liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"key":"2026010703472598000_15.12.e106054.71","doi-asserted-by":"crossref","first-page":"103788","DOI":"10.1016\/j.drugpo.2022.103788","article-title":"Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot","volume":"107","author":"Treloar","year":"2022","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.72","doi-asserted-by":"publisher","DOI":"10.1177\/2632084320947559"},{"key":"2026010703472598000_15.12.e106054.73","doi-asserted-by":"crossref","unstructured":"Strike CJ , Guta A . Patient-centred care and patient engagement to inform the use of psychosocial interventions with opioid substitution treatment: another path for Day & Mitcheson to follow, 2017. Available: https:\/\/doi.org\/https:\/\/doi.org\/10.1111\/add.13708","DOI":"10.1111\/add.13708"},{"key":"2026010703472598000_15.12.e106054.74","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-69"},{"key":"2026010703472598000_15.12.e106054.75","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2026010703472598000_15.12.e106054.76","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-48","article-title":"Enhancing the scoping study methodology: a large, inter-professional team\u2019s experience with Arksey and O\u2019Malley\u2019s framework","volume":"13","author":"Daudt","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2026010703472598000_15.12.e106054.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.03.013"},{"key":"2026010703472598000_15.12.e106054.78","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-21-00242"},{"key":"2026010703472598000_15.12.e106054.79","doi-asserted-by":"crossref","unstructured":"Peters MDJ , Godfrey C , McInerney P , et al . Chapter 11: scoping reviews (2020 version). In: Aromataris E , Munn Z , eds. JBI manual for evidence synthesis. 2020.","DOI":"10.46658\/JBIRM-20-01"},{"key":"2026010703472598000_15.12.e106054.80","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"},{"key":"2026010703472598000_15.12.e106054.81","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-22-00123"},{"key":"2026010703472598000_15.12.e106054.82","doi-asserted-by":"publisher","DOI":"10.1111\/wvn.12144"},{"key":"2026010703472598000_15.12.e106054.83","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/ACM.0000000000003109","article-title":"Re-visioning Academic Medicine Through a Constructionist Lens","volume":"95","author":"Rees","year":"2020","journal-title":"Acad Med"},{"key":"2026010703472598000_15.12.e106054.84","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/89.9.873"},{"key":"2026010703472598000_15.12.e106054.85","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/bmjebm-2020-111452","article-title":"Optimising the process for conducting scoping reviews","volume":"26","author":"Pawliuk","year":"2021","journal-title":"BMJ EBM"},{"key":"2026010703472598000_15.12.e106054.86","doi-asserted-by":"crossref","unstructured":"Aromataris E , Lockwood C , Porritt K , et al , eds. JBI manual for evidence synthesis. JBI, 2024. Available: https:\/\/jbi-global-wiki.refined.site\/space\/MANUAL","DOI":"10.46658\/JBIMES-24-01"},{"key":"2026010703472598000_15.12.e106054.87","unstructured":"Critical Appraisal Skills Programme (CASP) . CASP qualitative research checklist. 2023."},{"key":"2026010703472598000_15.12.e106054.88","doi-asserted-by":"crossref","first-page":"103364","DOI":"10.1016\/j.drugpo.2021.103364","article-title":"We are the researched, the researchers, and the discounted: The experiences of drug user activists as researchers","volume":"98","author":"Simon","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2026010703472598000_15.12.e106054.89","unstructured":"Madden A . \u2018There but not there\u2019: drug user representation in high level drug policy settings. University of New South Wales, 2022."},{"key":"2026010703472598000_15.12.e106054.90","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-021-00406-6","article-title":"Research led by people who use drugs: centering the expertise of lived experience","volume":"16","author":"Salazar","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2026010703472598000_15.12.e106054.91","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0091450920953635","article-title":"\u201cComing Out\u201d: Stigma, Reflexivity and the Drug Researcher\u2019s Drug Use","volume":"47","author":"Ross","year":"2020","journal-title":"Contemp Drug Probl"},{"key":"2026010703472598000_15.12.e106054.92","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022267","article-title":"Patient engagement, treatment preferences and shared decision-making in the treatment of opioid use disorder in adults: a scoping review protocol","volume":"8","author":"Marshall","year":"2018","journal-title":"BMJ Open"},{"key":"2026010703472598000_15.12.e106054.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108646"},{"key":"2026010703472598000_15.12.e106054.94","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000050"},{"key":"2026010703472598000_15.12.e106054.95","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-20-00167"},{"key":"2026010703472598000_15.12.e106054.96","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2026010703472598000_15.12.e106054.97","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"2026010703472598000_15.12.e106054.98","doi-asserted-by":"crossref","first-page":"601","DOI":"10.11124\/JBIES-22-00056","article-title":"Methods for developing quality indicators for evidence implementation: a scoping review protocol","volume":"21","author":"McArthur","year":"2023","journal-title":"JBI Evid Synth"},{"key":"2026010703472598000_15.12.e106054.99","doi-asserted-by":"publisher","DOI":"10.4300\/JGME-D-22-00621.1"},{"key":"2026010703472598000_15.12.e106054.100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/capr.12360","article-title":"Can I use TA? Should I use TA? Should I not use TA? Comparing reflexive thematic analysis and other pattern\u2010based qualitative analytic approaches","volume":"21","author":"Braun","year":"2021","journal-title":"Couns and Psychother Res"},{"key":"2026010703472598000_15.12.e106054.101","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000277"},{"key":"2026010703472598000_15.12.e106054.102","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-12-114","article-title":"What is the most appropriate knowledge synthesis method to conduct a review? Protocol for a scoping review","volume":"12","author":"Kastner","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026010703472598000_15.12.e106054.103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jclinepi.2015.11.022","article-title":"Conceptual recommendations for selecting the most appropriate knowledge synthesis method to answer research questions related to complex evidence","volume":"73","author":"Kastner","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2026010703472598000_15.12.e106054.104","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-016-0116-4","article-title":"A scoping review on the conduct and reporting of scoping reviews","volume":"16","author":"Tricco","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"2026010703472598000_15.12.e106054.105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.08.030"},{"key":"2026010703472598000_15.12.e106054.106","first-page":"45","article-title":"The Art of Coding and Thematic Exploration in Qualitative Research","volume":"15","author":"Williams","year":"2019","journal-title":"Int Manag Rev"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:49:52Z","timestamp":1767786592000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":106,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,17]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-106054"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106054","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}